True Freedom Investing LLC Purchases New Position in Avantor, Inc. $AVTR

True Freedom Investing LLC acquired a new stake in shares of Avantor, Inc. (NYSE:AVTR) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 39,010 shares of the company’s stock, valued at approximately $587,000.

Several other large investors have also recently added to or reduced their stakes in AVTR. Elevation Wealth Partners LLC boosted its holdings in shares of Avantor by 72.3% during the third quarter. Elevation Wealth Partners LLC now owns 2,803 shares of the company’s stock valued at $42,000 after acquiring an additional 1,176 shares during the period. Root Financial Partners LLC acquired a new stake in shares of Avantor in the third quarter valued at approximately $57,000. Nisa Investment Advisors LLC increased its stake in shares of Avantor by 40.8% in the third quarter. Nisa Investment Advisors LLC now owns 4,938 shares of the company’s stock valued at $74,000 after purchasing an additional 1,431 shares during the period. IFP Advisors Inc raised its holdings in shares of Avantor by 901.4% during the second quarter. IFP Advisors Inc now owns 5,858 shares of the company’s stock valued at $58,000 after buying an additional 5,273 shares during the last quarter. Finally, State of Wyoming bought a new stake in shares of Avantor during the second quarter valued at approximately $74,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Avantor Stock Performance

NYSE:AVTR opened at $16.05 on Monday. The company has a 50-day moving average of $15.49 and a 200-day moving average of $11.24. The firm has a market cap of $10.87 billion, a price-to-earnings ratio of 32.09, a price-to-earnings-growth ratio of 7.26 and a beta of 0.94. The company has a current ratio of 1.89, a quick ratio of 1.27 and a debt-to-equity ratio of 0.63. Avantor, Inc. has a twelve month low of $7.26 and a twelve month high of $17.45.

Avantor (NYSE:AVTR) last released its earnings results on Wednesday, October 28th. The company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.21 by $0.01. The business had revenue of $1.70 billion during the quarter, compared to analyst estimates of $1.64 billion. Avantor had a net margin of 5.08% and a return on equity of 9.79%. The business’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.22 earnings per share. Analysts forecast that Avantor, Inc. will post 0.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AVTR. Barclays raised their target price on Avantor from $15.00 to $16.00 and gave the company an “underweight” rating in a research report on Thursday. Robert W. Baird raised their price target on Avantor from $17.00 to $18.00 and gave the company an “outperform” rating in a report on Thursday. Wolfe Research raised shares of Avantor from a “strong sell” rating to a “hold” rating in a research note on Thursday, July 30th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $17.00 price target on shares of Avantor in a research report on Thursday. Finally, Royal Bank Of Canada raised their price objective on shares of Avantor from $14.00 to $17.00 and gave the company a “sector perform” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Avantor currently has an average rating of “Hold” and a consensus target price of $14.77.

About Avantor

Avantor, Inc is a global provider of mission-critical products and services used in the life sciences, healthcare, education, and advanced technology industries. The company supplies chemicals, reagents, laboratory consumables, equipment, and other materials used in research, development, manufacturing, and quality-control activities.

Avantor also provides specialized solutions for biopharmaceutical production, including materials and services that support drug development, biologics manufacturing, and other bioprocessing applications.